

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 14-11-2006

To,

The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 15-7-2006 TO BE PUBLISHED ON 15-11-2006
IN THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)
Controller of Patents & Designs
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

765/2006	<u>10-07-2006</u> Astra Zeneca AB, Sweden, (Priority 19-7-05 GB)	“ Therapeutic agents”
766/2006	Astra Zeneca AB, Sweden, (Priority 15-7-05 Sweden)	“ Therapeutic agents”
767/2006	Janssen Pharmaceutica N.V., Belgium (Priority 12-7-05 USA)	“ Methods of treating epileptogenesis”
768/2006	Janssen Pharmaceutica N.V., Belgium (Priority 12-7-05 USA)	“ Methods for neuroprotection”
769/2006	Wyeth, Holdings Corporation, USA (Priority 17-1-95 USA) Divisional	“ Pharmaceutically acceptable salt of tricyclic benzazepine vasopressin antagonists”
770/2006	Merck & Co, Inc., USA (Priority 20-7-05 USA)	“ HCV NS3 protease inhibitors”
771/2006	Novartis AG, Switzerland, (Priority 11-7-05 GB)	“ Organic compounds”
772/2006	Novartis AG, Switzerland, (Priority 7-11-2000 USA) Divisional	“ A salt of indolylmaleimide derivative, process for its production and pharmaceutical composition comprising thereof ”
773/2006	Tanabe Seiyaku Co, Ltd, Japan, (Priority 11-7-05 Japan)	“ An oxime derivative and preparations thereof ”
774/2006	Rieter Ingolstadt Spinnereimaschinenbau AG, Germany, (Priority 6-8-05 Germany)	“ Procedure for controlling of the draft of a drafting zone of a textile machine and textile machine ”

11-07-2006

775/2006	F. Hoffmann – La Roche AG, Switzerland, Divisional	“ Novel piperidine derivative “
776/2006	F. Hoffmann – La Roche AG, Switzerland, Divisional	“ Novel piperidines derivative “
777/2006	Merck Patent GmbH, Germany, (Priority 12-2-1998 USA) Divisional	“ Pharmaceutical composition comprising metformin and a fibrate”
778/2006	Merck & Co Inc, USA (Priority 28-5-96 USA) Divisional	“ Carbapenem antibiotic composition and method of preparation ”
779/2006	Wyeth, USA, (Priority 11-7-05 USA)	“ Glutamate Aggrecanase Inhibitors ”
780/2006	Wyeth, USA, (Priority 13-10-05 USA)	“ Methods for preparing glutamic acid derivatives ”
781/2006	Tetra Laval Holdings & Finance S.A, Pully, (Priority 11-7-05 Sweden)	“ Device for heating ”
782/2006	Novartis AG, Switzerland, (Priority 13-7-05 USA)	“ PPAR α/γ agonists and processes of preparing”
783/2006	TTrutzschler GmbH & Co. KG, Germany, (Priority 12-10-05 USA)	“ Apparatus in a spinning mill for making available a canless fibre sliver package (Feed Material) for a sliver – Fed spinning machine for example a draw frame ”
784/2006	Merck & Co Inc & Banyu Pharmaceutical Co, Ltd, USA, (Priority 19-7-05 USA)	“ Novel spirochromanone derivatives ”
785/2006	Merck & Co Inc & Sanyu Pharmaceutical Co, Ltd, USA, (Priority 18-7-05 USA)	“ Spiropiperidine beta- secretase inhibitors for the treatment of alzheimer’s disease”
	<u>12-07-2006</u>	
786/2006	Adelaide Research and innovation Pty Ltd,	“ Chelating agents for micronutrient fertilisers ”

Australia,
(Priority 12-7-05 Australia)

787/2006	Ultra Motor Co, Ltd, United Kingdom. (Priority 21-7-05 Russian)	“ All-wheel drive vehicle”
788/2006	1. Cytokinetics, Inc. 2. SmithKline Beecham Corporation, USA (Priority 09-5-02 USA) Divisional	“ A salt of the pyrimidinone compound and a pharmaceutical composition comprising thereof for treating cellular proliferative diseases and disorders”
789/2006	Bayer CropScience AG, Germany (Priority 16-8-05 Germany)	“ Synergistic insecticidal mixtures”
790/2006	Merck & Co, Inc. USA (Priority 22-7-05 USA)	“ HIV reverse transcriptase inhibitors”
791/2006	Wyeth Holdings Corporation USA (Priority 01-8-97 USA) Divisional	“ Pharmaceutically acceptable salts of substituted quinazoline compounds”
	<u>13-7-2006</u>	
792/2006	NASSA Limited, USA (Priority 15-7-05 USA)	“ Beverage kit and method for producing a non-fermented malt beverage”
793/2006	Genelabs Technologies, Inc, USA	“ Bicyclic heteroaryl derivatives for treating viruses”
794/2006	Sachtlebeb Chemic GmbH, Germany (Priority 13-7-05 Germany)	“ Marked inorganic additives”
795/2006	1. ENI S.p.A., 2. Enitecnologie S.p.A., Italy (Priority 22-7-05 Italy)	“ Process for the preparation of fischer-tropsch catalysts with a high mechanical, thermal and chemical stability”
796/2006	Wyeth, USA (Priority 15-7-05 USA)	“ Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof”
797/2006	Wyeth, USA (Priority 15-7-05 USA)	“ Highly biavailable oral delayed release dosage forms of o-desmethylvenlafaxine succinate”

798/2006	OS Health Care Co., Ltd., Republic of Korea (Priority 24-11-05 Korea)	Massage belt”
799/2006	Brothers Production (Pvt) Ltd. Sialkot, Pakistan.	“ Newly developed aero foam padding for boxing gloves”
	<u>14-7-2006</u>	
800/2006	Air Cdre Mansoor Malik National University of Science and Technology Islamabad, Pakistan.	“ Technomics”
801/2006	Glaxo Group Limited, United Kingdom (Priority 15-7-05 GB)	“ Novel compounds”
802/2006	Sanofi-Aventis France (Priority 22-7-05 France)	“ N-(arylalkyl)-1H-pyrrolopyridine-2-carbo xamide derivatives, preparation thereof and therapeutic use thereof”
	<u>15-7-2006</u>	
803/2006	Yuan Min An Enterprise Co, Ltd., Taiwan R.O.C.	“ Hockey Stick”
804/2006	Arif Anwar Surani Karachi, Pakistan.	“ Nanotechnology and a step towards termination of HIV/AIDS”

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicated their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

794/2004 Freyssinet International
(STUP),
France

“Reinforced soil structure having a facing and main reinforcement strips disconnected from the facing, and method for constructing such structure“

(Class: INT.CL. E02C, 2/06)

139156

The reinforced soil structure comprises a fill, a facing placed along a front face of the structure, main reinforcement strips disconnected from the facing and extending in a reinforced zone of the fill situated behind the front face, and secondary elements connected to the facing and extending in a zone of the fill which exhibits, with the reinforced zone, a common part where loads are transmitted between the main reinforcement strips and the secondary elements by the material of the fill.

795/2004 Honda Motor Co., Ltd.
Japan

“Apparatus for controlling an ignition timing of an engine”

(Class: INT.CL. F02D, 43/04)

139157

The application relates to an apparatus for controlling an ignition timing of engine, the said apparatus comprises;
an ignition timing calculator;

a mean effective pressure calculator;
a mean effective calculator and
a controller for controlling the set ignition timing to
converge to the optimum ignition timing.

796/2004 Materials Technics
Holding S.A.
Luxembourg

“An electric powder impregnation process for
;impregnating powder into a fibrous, filamentary
and/or porous network”

(Class: INT.CL.7: D06M, 23/08)

139158

This application relates to a process for impregnating a
fibrous, filamentary and/or porous net work with
powder, especially in order to produce a composite
comprising a continuous, rigid or flexible, matrix with
which said network is in intimate contact.

797/2004 Wyeth,
USA

Process for preparing pharmaceutical composition
comprising adrenergic antagonists and norepinephrine
reuptake inhibitors for treating vasomotor symptoms”

(Class: A61P, 25/00)

139159

The present invention relates to selective
adrenergica2B antagonists alone, selective
adrenergica2B antagonists in combination with
norepinephrine reuptake inhibitors (NR1) (as a single
compound or as a combination of two or more
compounds), or selective adrenergica2B antagonists in
combination with dual norepinephrine reuptake
inhibitors/serotonin reuptake inhibitors (NRI/SRI) (as
a single compound or as a combination of two or more

compounds) and methods of their use in the treatment of vasomotor symptoms.

806//2004 Muhammad Yaqub,
Arif Karim,
Faisal Ghazanfar,
Kamran Hafeez,
PCSIR, Karachi, Pakistan

“Microcontroller data acquisition system (MDAS)”

(Class: G08C, 15/00, G06F, 17/40)

139160

The Microcontroller data acquisition system (MDAS) is presented the design comprises of (i) single chip microcontroller (ii) internal RAM (random access memory) (iii) 12bit ADC (analog to digital converter) (iv) alphanumeric liquid crystal display (LCD) (v) 3-high input impedance amplifiers (vi) 4-channel analog multiplexer (vii) software controlled buzzer (viii) 3-input switches for user interaction (ix) a highly regulated power supply and (x) auto power off circuitry using 12-bit ADC and analog multiplexer, the microcontroller samples 4-analog inputs these signals are then converted to digital form for further processing and the result is displayed on the alphanumeric LCD screen three switches are provided for the activation of different modes of operation and software routines.

807/2004 Arif Karim,
Muhammad Yaqub,
Kamran Hafeez,
PCSIR, Karachi, Pakistan

“Portable pH meter”

(Class: INT.CL.7: G01N, 27/416)

139161

The portable pH meter is presented it comprises 12-bit ADC (Analog to Digital Converter) 4 ½ digits Liquid Crystal Display (LCD) high input impedance Pre-Amplifier temperature sensor and its preamplifier

circuitry (differential amplifier) with voltage divider network the analog signal from the pH electrode and temperature sensor is amplified and scaled-up in the pre-amplifier section the temperature effect is eliminated from the pH signal and the final analog signal is applied to the ADC the ADC then converts it to Digital form and prints pH and millivolt readings directly on the LCD display two knobs namely “Slop” and “Buffer” are provided for calibration with standard samples (buffers) it utilizes “Two Point Calibration Method” that is at least two buffers are required for calibration it offers two modes of operations “pH” (to show pH readings on display) and “mV” (to show millivolts from pH sensor) the instrument is powered up by 9V dry battery.

809/2004 Wyeth,
USA

“A process for preparing a pharmaceutical composition comprising [2-(8, 9-dioxo-2-, 6-diazabicyclo [5.2.0] Non-1 (7)-EN-2-YL) alkyl] phosphonic acid compound”

(Class: A61K, 31/46)

Comprises [8, 9, dioxo 2, 6-diazabicyclo [5.2.0] Na-1(7) EN-2-yl) alkyl] phosphonic acid process of its preparation, to its use in cerebral vascular disorder.

811/2004 Sanofi-Aventis,
France

“A pharmaceutical composition comprising a pyrazole derivative for use in the prevention and treatment of dyslipidaemias and of diseases related to dyslipidaemias and/or obesity”

(Class: A61K, 31/415)

139163

Comprises N-piperidino-5-(4-bromophenyl)-1-(2, 4-dichlorophenyl)-4-ethylpyrazole-3-carboximide, to pharmaceutical composition containing it, to its use as antidiabetic agent.

813/2004 USTER Technologies AG,
Switzerland

“Method of processing signals obtained from scanning textile fabrics”

(Class: G11B, 13/08)

Characterized in that the values for pre-selected parameter are derived from the signals; in that limit values which serve to determine faults in the fabric are predetermined for the values of the parameter, in that value ranges which define categories of faults in the fabric are determined for the values of parameters.

817/2004 Sandoz AG,
Switzerland

“An antibiotic composition comprising coated micropellets”

(Class: A61K, 9/28)

Comprising coated micropellets, comprise

- i) a core comprising at least one antibiotic
- ii) an inner coating comprising at least one cellulose polymer which is not an enteric coating polymer
- iii) an outer coating comprising at least one enteric coating polymer, wherein said coated micropillets have a mean particle size of about 100 μ m to about 650 μ m

824/2004 Telenor ASA,
Norway

“Backward and forward non-normalized link weight analysis method, system”

(Class: G01G, 19/40)

139166

Comprising a calculator contigence to calcab an authority like weight for said node and a hub like weight for said node, using respectively a non compound, non normalized formulas operator and a non-compound, non-normalized back work operator, said calculations being mathematically decoupled.

833/2004 Wyeth,
USA

“Methods for the preparation of [2-[8, 9)-dioxo-2, 6-diaza-bicyclo [5.2.0]-Non-1 (7)-EN-2-yl] ethyl} posponic acid and esters thereof”

(Class: INT.CL.7: C08D, 245/04)

139167

This application relates to an improved process for preparation of {2-(8, 9)-dioxo-2,

6-diazabicyclo[5.2.0]-non-1(7)-en-2-yl}ethyl]

prosponic acid and ester thereof.

836/2004 Ophthalmos Limited,
Cambridge

“Ophthalmoscope”

(Class: INT.CL.7: A61B, 3/13)

139168

This application relates to an aphthalmoscope and especially, but not exclusively to an ophthalmoscope which is simple, inexpensive and without lens.

843/2004 Wyeth,
USA

“Process for preparing extended release
pharmaceutical dosage form”

(Class: INT, CL. 7 A61K, 9/00)

139169

1. This invention relates to a process for preparing an oral pharmaceutical or veterinary dosage form for extended release of a biologically active drug which

is soluble in gastrointestinal media, which process comprises.

(a). (i) melt granulating a mixture of the biologically active drug and a first insoluble substance which is substantially insoluble in gastrointestinal media and compressing the resulting granules to provide a core, or (ii) dry blending the active drug and the first insoluble substance and compressing the mixture to provide a core,.

(b). spray coating the core of step (a) with media and a component which is soluble in gastrointestinal (ii) a melt of the second substance containing a dispersion of the soluble component; and

(c) drying if appropriate.

850/2004 Wyeth,
USA

“A process for preparing sustained release pharmaceutical composition comprising dopaminergic compound”

(Class: INT.CL.7: A61K, 9/22, 9/52)

This invention relates to sustained release composition of dopaminergic compounds, including S-2-[(benzylamino)-methyl]-2, 3, 8, 9-tetrahydro-7H1, 4-dioxino [2, 3-e] indol-8-one (apindore) and pharmaceutically acceptable salts thereof.

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

138966	Regeneron Pharmaceuticals, Inc, USA	431/2004
138967	1. Apputhurai Chandrakumar, 2. Kulanathan Kularajan GB,	446/2004
138968	Eli Lilly and Co, USA	450/2004
138969	Otsuka Pharmaceutical Co, Ltd., Japan	451/2004
138970	1. ENI S.P.A., Italy 2. Institut Francais Du Petrole., France 3. Enitecnologie S.p.A., Italy	462/2004
138971	Euro-Celtique S.A.,	471/2004

Luxembourg

138972	Urea Casale S.A., Switzerland	473/2004
138973	Madrigal Sports (Pvt.) Ltd., Sialkot, Pakistan	480/2004
138974	AstraZeneca AB, Sweden	517/2004
138975	Wyeth, USA	771/2004
138976	Otsuka Pharmaceutical Co. Ltd., Japan	1198/2005

(Mrs. Yasmeen Abbasi)
Controller of Patents & Designs
Tel: 9215488